Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Christopher Starr Sells 8,400 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Christopher Starr sold 8,400 shares of Monopar Therapeutics stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $78.50, for a total value of $659,400.00. Following the transaction, the director directly owned 5,173 shares of the company’s stock, valued at $406,080.50. This trade represents a 61.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Up 0.4%

Shares of Monopar Therapeutics stock traded up $0.32 on Monday, hitting $78.29. The company’s stock had a trading volume of 128,260 shares, compared to its average volume of 210,743. Monopar Therapeutics Inc. has a 52-week low of $50.07 and a 52-week high of $124.82. The company has a market capitalization of $525.33 million, a P/E ratio of -36.08 and a beta of 1.50. The firm has a fifty day moving average price of $107.25 and a 200-day moving average price of $82.88.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. As a group, analysts expect that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MNPR. Bank of New York Mellon Corp acquired a new stake in Monopar Therapeutics in the 2nd quarter worth about $7,124,000. Bank of America Corp DE increased its stake in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares during the period. The Manufacturers Life Insurance Company purchased a new position in shares of Monopar Therapeutics during the 1st quarter worth about $250,000. Finally, Siren L.L.C. boosted its position in shares of Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on MNPR. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Zacks Research lowered shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. BTIG Research raised their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a report on Thursday, July 23rd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.